Shandong Bailong Chuangyuan Bio-Tech (605016) Fundamentals 2026 — P/E 22.4x, Revenue Analysis | SniperIQ
Shandong Bailong Chuangyuan Bio-Tech (605016) is a CN-listed Consumer Defensive company in Packaged Foods with a market capitalization of ¥9.8B, trading at ¥23.28 on the SHH. This SniperIQ fundamentals page covers Shandong Bailong Chuangyuan Bio-Tech's valuation (P/E 22.4x, P/B 4.7x), profitability (net margin 28.0%), revenue (¥1.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shandong Bailong Chuangyuan Bio-Tech's market cap?
Shandong Bailong Chuangyuan Bio-Tech (605016) has a market capitalization of approximately ¥9.8B, trading at ¥23.28 on the SHH. Market cap moves with the live share price.
What is Shandong Bailong Chuangyuan Bio-Tech's P/E ratio?
Shandong Bailong Chuangyuan Bio-Tech's trailing twelve-month P/E ratio is 22.4x, with a price-to-book (P/B) of 4.7x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Shandong Bailong Chuangyuan Bio-Tech?
Shandong Bailong Chuangyuan Bio-Tech runs a net profit margin of 28.0%, a gross margin of 43.0%, and an operating margin of 32.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shandong Bailong Chuangyuan Bio-Tech generate?
Shandong Bailong Chuangyuan Bio-Tech reported revenue of ¥1.4B for fiscal year 2025, with net income of ¥369M and earnings per share (EPS) of 0.88. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shandong Bailong Chuangyuan Bio-Tech pay a dividend?
Shandong Bailong Chuangyuan Bio-Tech offers a trailing dividend yield of about 1.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shandong Bailong Chuangyuan Bio-Tech financially healthy?
Shandong Bailong Chuangyuan Bio-Tech carries a debt-to-equity ratio of 0.24x and a current ratio of 2.51x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shandong Bailong Chuangyuan Bio-Tech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shandong Bailong Chuangyuan Bio-Tech (605016) the key facts are: market cap ¥9.8B, P/E 22.4x, revenue ¥1.4B, 52-week range 18.75-29.1. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Shandong Bailong Chuangyuan Bio-Tech's full fundamentals live
Get Shandong Bailong Chuangyuan Bio-Tech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.